Overall experience with NovoSeven®

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 4 SUPPL. 1, 2000, Pages

  Negrier C ^a   Lienhart, A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Haemophilia; Inhibitors; NovoSeven ; Recombinant factor VIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANTIBODY; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; BLOOD CLOTTING; CONFERENCE PAPER; DOSE RESPONSE; DRUG SAFETY; HEMOPHILIA; HUMAN; LIVER FAILURE; PRIORITY JOURNAL; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA; CLINICAL TRIAL; HEMOPHILIA A; IMMUNOLOGY; REVIEW;

ANTIBODIES; CLINICAL TRIALS; FACTOR VII; FACTOR VIIA; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 0343238468     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200004001-00005     Document Type: Conference Paper

References (43)

1. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with a low-purity factor VIII. Lancet 1993; 342: 462-464.
2. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia. Safety, efficacy and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New Engl J Med 1993; 328: 453-459.
3. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-2435.
4. Katz J. Prevalence of factor IX inhibitors among patients with hemophilia B - results of a large-scale North American survey. Haemophilia 1996; 2: 28-31.
5. Green D, Lechner KA. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-203.
6. Aledort LM. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994; 47: 208-217.
7. Lusher JM, Shapiro SS, Palacak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. New Engl J Med 1980; 303: 421-425.
8. Négrier C, GoudemandJ, Sultan Y, Bertrand M, Rothschild C, Lauroua P, and the members of the French FEIBA study group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-1119.
9. Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-29.
10. Morrison AE, Ludlam CA, Kessler CM. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-1520.
11. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor inhibitors - twenty years' 'Bonn protocol' Vox Sang 1996; 70 (suppl 1): 30-35.
12. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-317.
13. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9: 119-128.
14. Hay CR, Négrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-1467.
15. Hedner U, Schulman S, Alberts KA, Blomback M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
16. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group Haemophilia 1998; 4: 790-798.
17. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven®) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
18. Laurian Y, Goudemand J, Négrier C, Vicariot M, Marques-Verdier A, Fonlupt J, et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998; 9 (suppl 1): 155-156.
19. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-26.
20. Ingerslev J, Friedman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (suppl 1); 131-134.
21. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
22. Rice KM, Savidge GF. NovoSeven® (recombinant factor VIIa) in central nervous system bleeds. Haemostasis 1996; 26 (suppl 1): 131-134.
23. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-436.
24. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, Levi M, Peerlinck K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors; Experience in the Netherlands and Belgium. Neth J Med 1998; 53: 249-255.
25. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis 1991; 21: 1-4.
26. Stieltjes N, Ounnoughene N, Vassilieff D, Sultan Y. Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC. Thromb Haemost 1997; 77: 50 (abstract).
27. Lottenburg R, Kentro TB, Kitchens CS. Acquired haemophilia. A natural history study of 16 patients with factor VIII inhibitor receiving little or no therapy. Arch Intern Med 1987; 147: 1077-1081.
28. Kristensen J, Killander A, Hippe E, Helleberg C, Elegard J, Holm M. et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (suppl 1): 159-164.
29. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-982.
30. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nose bleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
31. Revesz T, Arets B, Bierings M, van den Bos C, Duval E. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 353.
32. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven®) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (suppl 1): 150-154.
33. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9 (suppl 1): 119-123.
34. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-1937.
35. Kasper CK. Postoperative thromboses in hemophilia. N Engl J Med 1973; 289: 160.
36. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors: benefits and limitations. Semin Hematol 1994; 31: 49-52.
37. Ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212.
38. Diness V, Bregengaard C, Erhardtsen E, Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thrombosis Res 1992; 67: 233-241.
39. Roberts HR. Clinical experience with activated factor VIIa: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9 (suppl 1): 115-8.
40. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-10.
41. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, et al. Factor IX inhibitors and anaphylaxis in haemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-27.
42. Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa). Eur J Haematol Suppl 1998; 63: 18-23.
43. Hedner U. Dosing and monitoring NovoSeven® treatment. Haemostasis 1996; 26 (suppl 1): 102-108.